Summary
Neonatal bacterial meningitis has a relatively low incidence in developed countries, but continues to cause morbidity and mortality despite advances in antimicrobial therapy. Bacterial pathogens commonly associated with neonatal meningitis include Group B streptococci, Escherichia coli K1 and other coliforms, Listeria monocytogenes and staphylococci. As it can be difficult to differentiate meningitis from septicaemia in neonates, empirical antibiotic therapy should be effective for both. Selection of an empirical antibiotic regimen should be based on: (a) bacterial prevalence and susceptibility; (b) drug characteristics; (c) postnatal age at the onset of disease; and (d) patient-specific factors. A penicillin in combination with an aminoglycoside or cefotaxime is commonly used in empirical therapies. The increased risk of staphylococcal infection in older neonates requires consideration of an antistaphylococcal antibiotic in the empirical therapy regimen. Once a causative organism has been identified, antimicrobial therapy should be directed towards that pathogen. Duration of therapy remains empirical, but should be at least 7 days for documented bacterial meningitis. Viral meningitis continues to have a high mortality despite the availability of antiviral agents.
Adjunctive therapies may further reduce the morbidity and mortality of meningitis. While most of these therapeutic options have not been investigated in neonates, they may prove to be of benefit in the future. Anti-inflammatory agents, such as glucocorticoids, nonsteroidal anti-inflammatory agents and immunoglobulin, may modulate the inflammatory response of a meningeal infection. Other possible therapies in neonatal meningitis include cerebral blood flow modulators and disease prevention with maternal vaccines and perinatal antibiotics. Practical aspects of drug therapy such as route of administration and serum drug concentration monitoring can improve both drug therapy and patient outcome. While antibiotics have greatly improved the treatment outcome of neonatal meningitis, it is clear that additional intervention will be required to increase cure rates and reduce sequelae.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adelman C, Under N, Levi H. Auditory nerve and brain stem evoked response thresholds in infants treated with gentamicin as neonates. Annals of Otology, Rhinology and Laryngology 98: 283–286, 1989
Ashwal S, Stringer W, Tomasi L, Schneider S, Thompson J, et al. Cerebral blood flow and carbon dioxide reactivity in children with bacterial meningitis. Journal of Pediatris 117: 523–530, 1990
Baker CJ, Noya FJD. Potential use of intravenous immune globulin for group B streptococcal infection. Reviews of Infectious Diseases 12 (Suppl. 4): S476–S482, 1990
Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, et al. Immunization of pregnant women with a polysaccharide vaccine of Group B streptococcus. New England Journal of Medicine 319: 1180–1185, 1988
Baker CJ, Rench MA, Noya FJD, Garcia-Prats JA, et al. Role of intravenous immunoglobulin in prevention of late-onset infection in low-birth-weight neonates. Reviews of Infectious Diseases 12 (Suppl. 4): S463–S469, 1990
Band JD, Clegg HW, Hayes PS, Facklam RR, Stringer J, Dixon RE. Transmission of group B streptococci: Traced by multiple epidemiologic markers. American Journal of Diseases of Childhood 135: 355–358, 1981
Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate: a critical review of the pharmacokinetic-pharmacodynamic interface (Part 1). Clinical Pharmacokinetics 14: 189–216, 1988
Bryan CS, John Jr JF, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. American Journal of Diseases of Children 139: 1086–1089, 1985
Buchanan N. Aminoglycoside monitoring in neonates — a reappraisal. Australian and New Zealand Journal of Medicine 5: 457–459, 1985
Ch’ien LT, Whitley RJ, Nahmias AJ, Lewin EB, Linnemann CC, et al. Antiviral chemotherapy and neonatal herpes simplex virus infection: a pilot study — experience with adenine arabinoside (ARA-A). Pediatrics 55: 678–685, 1975
Cottrell JE, Robustelli A, Post K, Turndorf H. Furosemide and mannitol induced changes in intracranial pressure and serum osmolality and electrolytes. Anesthesiology 47: 28–30, 1977
Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clinical Pharmacy 6: 652–654, 1987
Freidman CA, Wender DF, Temple DM, Rawson JE. Intravenous gamma globulin as adjunct therapy for severe group B streptococcal disease in the newborn. American Journal of Perinatology 7: 1–4, 1990
Girgis NL, Farid Z, Mikhail IA, Farrag I, Sultan Y, et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatric Infectious Disease Journal 8: 848–851, 1989
Gould T, Roberts RJ. Therapeutic problems arising from the use of the intravenous route of drug administration. Journal of Pediatrics 95: 465–471, 1979
Gruskay J, Harris MC, Costarino AT. Neonatal Staphylococcus epidermidis meningitis with unremarkable CSF examination results. American Journal of Diseases of Children 143: 580–582, 1989
Hall SL. Coagulase-negative staphylococcal infections in neonates. Pediatric Infectious Disease Journal 10: 57–67, 1991
Kalenga M, Devos D, Moulin D, Verellen G, Bertrand JM. The need for pharmacokinetic monitoring of gentamicin in critically ill neonates. Developmental Pharmacology and Therapeutics 7 (Suppl. 1): 130–133, 1984
Klein JO, Feigin RD, McCracken GH. Report of the task force on the diagnosis and management of meningitis. Pediatrics 78 (Suppl.): 959–979, 1986
Klein JO, Marcy SM. Bacterial sepsis and meningitis. In Remington JS, Klein JO (Eds) Infectious Diseases of the Fetus and Newborn, 2nd ed. pp 679–735, WB Saunders Co., Philadelphia, 1983
Koren G. Clinical pharmacology of antimicrobial drugs during development: are infants and children different? In Koren G et al. (Eds) Antimicrobial therapy in infants and children, pp. 47–53, Marcel Dekker Inc., New York, 1988
Lebel MH, Freij BJ, Syrogiannopoulos G, Chrane DF, Hoyt MJ, et al. Dexamethasone therapy for bacterial meningitis. New England Journal of Medicine 319: 964, 1988
Lee SP, Lipsky BA, Teefey SA. Gallbladder sludge and antibiotics. Pediatric Infectious Disease Journal 9: 422–423, 1990
McCracken Jr GH. Aminoglycoside toxicity in infants and children. American Journal of Medicine 80 (Suppl. 6B): 172–178, 1986
McCracken Jr GH, Lebel MH. Dexamethasone therapy for bacterial meningitis in infants and children. American Journal of Diseases of Children 143: 287–289, 1989
McCracken Jr GH, Mize SG. A controlled study of intrathecal antibiotic therapy in Gram-negative enteric meningitis in infancy. Report of the neonatal meningitis cooperative study group. Journal of Pediatrics 89: 66, 1976
McCracken Jr GH, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in Gram-negative bacillary meningitis of infancy. Lancet 1: 787, 1980
McCracken Jr GH, Nelson JD, Kaplan SL, Overturf GD, Rodriguez WJ, et al. Consensus report: antimicrobial therapy for bacterial meningitis in infants and children. Pediatric Infectious Disease Journal 6: 501–505, 1987
McCracken Jr GH, Sarff LD, Glode MP, Mize SG, Schiffer MS, Robbins JB. Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet 2: 246–250, 1974
Moore RD, Smith CR, Lietman PC. The association of aminoglycoside plasma level with therapeutic outcome in Gram-negative pneumonia. American Journal of Medicine 77: 657–662, 1984
Mustafa MM, Lebel MH, Ramilo O, Olsen KD, Reisch JS, et al. Correlation of interleukin-1B and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. Journal of Pediatrics 115: 208–213, 1989
Nahata MC. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy 33: 302–304, 1987
Nahata MC. Serum concentrations and adverse effects of chlor-amphenicol in pediatric patients. Chemotherapy 33: 322–327, 1987
Nahata MC, Miller MA. Diarrhoea associated with ceftriaxone and its implications in paediatric patients. Journal of Clinical Pharmacy and Therapeutics 14: 305–307, 1989
Ng PC, Thompson MA, Dear PRF. Dexamethasone and infection in preterm babies: a controlled study. Lancet 2: 54–56, 1989
Odio CM, Faingezicht I, Paris M, Nassar M, Baltodano A, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. New England Journal of Medicine 324: 1525–1531, 1991
Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clinical Pharmacokinentics 19: 280–316, 1990
Radetsky M. Duration of treatment in bacterial meningitis: a historical inquiry. Pediatric Infectious Disease Journal 9: 2–9, 1990
Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clinical Pharmacy 6: 655–658, 1987
St Gerne III JW, Polin RA. Neonatal sepsis. Progress in diagnosis and management. Drugs 36: 784–800, 1988
Sande MA, Tauber MG, Scheid WM, McCracken Jr GH. Report of a second workshop: Pathophysiology of bacterial meningitis. Pédiatrie Infectious Disease Journal 8: 901–918, 1989
Schlech III WF, Ward JI, Band JD, Hightower A, Fraser DW, Broome C. Bacterial meningitis in the United States, 1978through 1981: The national bacterial meningitis surveillance study. Journal of The American Medical Association 253: 1749–1754, 1985
Stewart CF, Hampton EM. Effect of maturation of drug disposition in pediatric patients. Clinical Pharmacy 6: 548–564, 1987
Stone KM, Brooks CA, Guinan ME, Alexander ER. National Surveillance for neonatal herpes simplex virus infection. Sexually Transmitted Diseases 16: 152–156, 1989
Word BM, Klein JO. Therapy of bacterial sepsis and meningitis in infants and children: 1989poll of directors of program s in pediatric infectious diseases. Pediatric Infectious Disease Journal 8: 635–637, 1989
Whitley RJ. Herpes simplex virus infections of the central nervous system: encephalitis and neonatal herpes. Drugs 42: 406–427, 1991
Whitley R, Arvin A, Prober C, Burchett S, Corey L, et al. A con trolled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. New England Journal of Medicine 324: 444–449, 1991
Whitley R, Arvin A, Prober C, Corey L, Burchett S, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. New England Journal of Medicine 324: 450–454, 1991
Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 66: 495–501, 1980
Whitley RJ, Yeager A, Kartus P, Bryson Y, Connor JD, et al. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics 72: 778–785, 1983
Wright PF, Kaiser AB, Bowman CM, McKee KT, Trujillo H, et al. The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. Journal of Infectious Diseases 143: 141–147, 1981
Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, et al. Treatment of gram-negative and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine 324: 429–436, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paap, C.M., Bosso, J.A. Treatment Options for the Pharmacological Therapy of Neonatal Meningitis. Drugs 43, 700–712 (1992). https://doi.org/10.2165/00003495-199243050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199243050-00006